t
Pfizer Inc. transferred 2,364,050,902 ordinary shares in Haleon plc from Wealth Nominees Limited to BofA Securities, Inc. as its nominee holding on August 3, 2022. This action maintained Pfizer Inc.'s total voting rights in Haleon plc at 32.00% (2,955,063,626 shares), with no change since its last notification on July 18, 2022. This announcement corrects a previous filing by clarifying BofA Securities, Inc. as the nominee entity.
| Date | 9 Aug 2022 |
| Time | 14:30:05 |
| Category | Holding(s) in company |
| ID | 4476V |
The following replaces the 'Holding(s) in Company' announcement released by Haleon plc (the "Company") on 4 August 2022 at 12:00 under RNS No 9394U.
This version corrects and replaces the notification made by Pfizer Inc. to the Company on 3 August 2022, as the Bank of America nominee entity is "BofA Securities, Inc.", instead of "N.Y. Nominees Limited".
The full amended text is shown below.
Haleon plc
TR-1: Standard form for notification of major holdings
1. Issuer Details
ISIN
GB00BMX86B70
Issuer Name
Haleon plc
UK or Non-UK Issuer
UK
2. Reason for Notification
Other
Comments
Change of nominee shareholder from Wealth Nominees Limited to BofA Securities, Inc.. See section 11 (additional information).
3. Details of person subject to the notification obligation
Name
Pfizer Inc.
City of registered office (if applicable)
New York
Country of registered office (if applicable)
United States of America
4. Details of the shareholder
|
Name |
City of registered office |
Country of registered office |
|
Guaranty Nominees Limited |
Bournemouth |
United Kingdom |
|
BofA Securities, Inc. |
London |
United Kingdom |
5. Date on which the threshold was crossed or reached
03-Aug-2022
6. Date on which Issuer notified
03-Aug-2022
7. Total positions of person(s) subject to the notification obligation
|
% of voting rights attached to shares (total of 8.A) |
% of voting rights through financial instruments (total of 8.B 1 + 8.B 2) |
Total of both in % (8.A + 8.B) |
Total number of voting rights held in issuer |
|
|
Resulting situation on the date on which threshold was crossed or reached |
32.000000 |
0.000000 |
32.000000 |
2955063626 |
|
Position of previous notification (if applicable) |
32.000000 |
0.000000 |
32.000000 |
|
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
8A. Voting rights attached to shares
|
Class/Type of shares ISIN code(if possible) |
Number of direct voting rights (DTR5.1) |
Number of indirect voting rights (DTR5.2.1) |
% of direct voting rights (DTR5.1) |
% of indirect voting rights (DTR5.2.1) |
|
Ordinary Shares GB00BMX86B70 |
|
2364050902 |
|
25.600000 |
|
Restricted ADRs |
|
591012724 |
|
6.400000 |
|
Sub Total 8.A |
2955063626 |
32.000000% |
||
8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))
|
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Number of voting rights that may be acquired if the instrument is exercised/converted |
% of voting rights |
|
|
|
|
|
|
|
Sub Total 8.B1 |
|
|
|
|
8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))
|
Type of financial instrument |
Expiration date |
Exercise/conversion period |
Physical or cash settlement |
Number of voting rights |
% of voting rights |
|
|
|
|
|
|
|
|
Sub Total 8.B2 |
|
|
|
||
9. Information in relation to the person subject to the notification obligation
1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.
|
Ultimate controlling person |
Name of controlled undertaking |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
|
|
|
|
|
|
10. In case of proxy voting
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional Information
In relation to section 2 (reason for the notification), this notification is for information purposes only in relation to the transfer of Pfizer Inc. ("Pfizer")'s 2,364,050,902 ordinary shares in the capital of Haleon plc ("Haleon"), which were initially held by Wealth Nominees Limited as nominee holding on behalf of Pfizer, to BofA Securities, Inc. as nominee holding on behalf of Pfizer. This transfer completed on 3 August 2022.
Since our last notification on 18 July 2022, there has been no change to the number of voting rights in Haleon held by Pfizer, and Pfizer has not crossed any shareholding thresholds.
This version corrects and replaces the notification made on 3 August 2022. The Bank of America nominee entity is "BofA Securities, Inc.", instead of "N.Y. Nominees Limited".
12. Date of Completion
08-Aug-2022
13. Place Of Completion
New York, USA